USA - NASDAQ:RPRX - GB00BMVP7Y09 - Common Stock
Taking everything into account, RPRX scores 5 out of 10 in our fundamental rating. RPRX was compared to 191 industry peers in the Pharmaceuticals industry. While RPRX has a great profitability rating, there are quite some concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on RPRX.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 5.57% | ||
ROE | 16.08% | ||
ROIC | 8.5% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 79.84% | ||
PM (TTM) | 44.28% | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.1 | ||
Debt/FCF | 11.22 | ||
Altman-Z | 1.72 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.26 | ||
Quick Ratio | 1.26 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 9.33 | ||
Fwd PE | 7.2 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 30.14 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.42% |
36.85
+0.01 (+0.03%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.42% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 9.33 | ||
Fwd PE | 7.2 | ||
P/S | 9.32 | ||
P/FCF | 30.14 | ||
P/OCF | 8.93 | ||
P/B | 3.39 | ||
P/tB | 3.96 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 5.57% | ||
ROE | 16.08% | ||
ROCE | 10.75% | ||
ROIC | 8.5% | ||
ROICexc | 9.3% | ||
ROICexgc | 9.89% | ||
OM | 79.84% | ||
PM (TTM) | 44.28% | ||
GM | N/A | ||
FCFM | 30.93% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.1 | ||
Debt/FCF | 11.22 | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | 73.45% | ||
Interest Coverage | -8.39 | ||
Cash Conversion | N/A | ||
Profit Quality | 69.86% | ||
Current Ratio | 1.26 | ||
Quick Ratio | 1.26 | ||
Altman-Z | 1.72 |